UBS disclosed Johnson & Johnson (NYSE:JNJ), hiking its price target to $144.00 earlier today
- Updated: October 19, 2016
Indicating a possible upside of 0.25%, UBS bumped up the target price of Johnson & Johnson (NYSE:JNJ) to $144.00
Previously on 10/03/2016, Vetr Inc. released a statement about Johnson & Johnson (NYSE:JNJ) increased the target price from $0.00 to $123.14. At the time, this indicated a possible upside of 0.05%.
Just yesterday Johnson & Johnson (NYSE:JNJ) traded -0.37% lower at $115.41. Johnson & Johnson’s 50-day moving average is $118.58 and its 200-day moving average is $117.61. The last stock price is down -2.23% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 2,359,778 shares of JNJ traded hands, down from an average trading volume of 6,148,870
Recent Performance Chart
Johnson & Johnson has 52 week low of $94.28 and a 52 week high of $126.07 with a PE ratio of 21.43 and has a market capitalization of $0.
In addition to UBS reporting its stock price target, a total of 18 brokerages have issued a research note on the company. The average stock price target is $117.44 with 0 analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.
More About Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.